These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33036137)

  • 1. Targeting DNA Repair Pathways in Hematological Malignancies.
    Alhmoud JF; Mustafa AG; Malki MI
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33036137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormalities of DNA repair mechanisms in common hematological malignancies.
    Economopoulou P; Pappa V; Papageorgiou S; Dervenoulas J; Economopoulos T
    Leuk Lymphoma; 2011 Apr; 52(4):567-82. PubMed ID: 21438828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA repair pathways as guardians of the genome: Therapeutic potential and possible prognostic role in hematologic neoplasms.
    Rahimian E; Amini A; Alikarami F; Pezeshki SMS; Saki N; Safa M
    DNA Repair (Amst); 2020 Dec; 96():102951. PubMed ID: 32971475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.
    Ahmadi SE; Rahimi S; Zarandi B; Chegeni R; Safa M
    J Hematol Oncol; 2021 Aug; 14(1):121. PubMed ID: 34372899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of drug resistance in hematologic malignancies.
    Dalton WS
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities.
    Fulda S
    Leukemia; 2014 Jul; 28(7):1414-22. PubMed ID: 24487414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the apoptosis pathway in hematologic malignancies.
    Zaman S; Wang R; Gandhi V
    Leuk Lymphoma; 2014 Sep; 55(9):1980-92. PubMed ID: 24295132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the telomere and telomerase system in hematological malignancies.
    Ram R; Uziel O; Lahav M
    Leuk Lymphoma; 2005 Aug; 46(8):1121-35. PubMed ID: 16085552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.
    Wu H; Medeiros LJ; Young KH
    Blood Rev; 2018 Jan; 32(1):8-28. PubMed ID: 28802908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage response and hematological malignancy.
    Takagi M
    Int J Hematol; 2017 Sep; 106(3):345-356. PubMed ID: 28374143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and clinical prospects of Notch inhibitors in the therapy of hematological malignancies.
    Nefedova Y; Gabrilovich D
    Drug Resist Updat; 2008 Dec; 11(6):210-8. PubMed ID: 18951834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance-related microRNAs in hematological malignancies: translating basic evidence into therapeutic strategies.
    Xie L; Jing R; Qi J; Lin Z; Ju S
    Blood Rev; 2015 Jan; 29(1):33-44. PubMed ID: 25263425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncoding RNAs in DNA Damage Response: Opportunities for Cancer Therapeutics.
    Arjumand W; Asiaf A; Ahmad ST
    Methods Mol Biol; 2018; 1699():3-21. PubMed ID: 29086365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Notch as a Therapeutic Approach for Human Malignancies.
    Platonova N; Lesma E; Basile A; Bignotto M; Garavelli S; Palano MT; Moschini A; Neri A; Colombo M; Chiaramonte R
    Curr Pharm Des; 2017; 23(1):108-134. PubMed ID: 27719637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.
    Flynn MJ; Zammarchi F; Tyrer PC; Akarca AU; Janghra N; Britten CE; Havenith CE; Levy JN; Tiberghien A; Masterson LA; Barry C; D'Hooge F; Marafioti T; Parren PW; Williams DG; Howard PW; van Berkel PH; Hartley JA
    Mol Cancer Ther; 2016 Nov; 15(11):2709-2721. PubMed ID: 27535974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MUC1 in hematological malignancies.
    Stroopinsky D; Kufe D; Avigan D
    Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy regulation and its dual role in blood cancers: A novel target for therapeutic development (Review).
    Jin S; Wei J; You L; Liu H; Qian W
    Oncol Rep; 2018 Jun; 39(6):2473-2481. PubMed ID: 29658589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging targets for hematological malignancies.
    Cilloni D; Frassoni F; Saglio G
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):548-58. PubMed ID: 20812146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon alpha2 in the treatment of hematological malignancies. Status and perspectives.
    Hasselbalch HC
    Curr Drug Targets; 2011 Mar; 12(3):387-91. PubMed ID: 21143152
    [No Abstract]   [Full Text] [Related]  

  • 20. Chromosome breaks and genomic instability.
    Jasin M
    Cancer Invest; 2000; 18(1):78-86. PubMed ID: 10701370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.